“Assessing VA’s Risks for Drug Diversion”
Keith Berge, M.D.
Consultant in Anesthesiology, Chair, Mayo Clinic Enterprise-wide Medication Diversion Prevention Committee, on behalf of Mayo Clinic
Carolyn Clancy, M.D.
Deputy Under Secretary for Health for Organizational Excellence, Veterans Health Administration, on behalf of U.S. Department of Veterans Affairs
Deputy Assistant Inspector General for Audits and Evaluations, on behalf of VA Office of Inspector General
Michael H. Valentino, R. Ph. , MHSA
(Accompanying Dr. Lynch) Chief Consultant, Veterans Health Administration, Pharmacy Benefits Management Services, on behalf of U.S. Department of Veterans Affairs
Emorfia Valkanos, R. Ph.
(Accompanying Mr. Dahl) Health Systems Specialist, Office of Healthcare Inspections, on behalf of VA Office of Inspector General
Randall B. Williamson
Director, Healthcare Team, U.S. Government Accountability Office, on behalf of U.S. Government Accountability Office